Adipose-derived mesenchymal stem cell transplantation for treatment of liver failure

doi:10.3969/j.issn.2095-4344.2016.32.015

Abstract

Abstract:

BACKGROUND: Studies have found that both bone marrow mesenchymal stem cells and umbilical cord mesenchymal stem cells have therapeutic effects on liver failure, but little is reported on adipose-derived mesenchymal stem cell transplantation for treatment of liver failure.
OBJECTIVE: To discuss the therapeutic effect of adipose-derived mesenchymal stem cell transplantation on rat liver failure.
METHODS: Forty-five Sprague-Dawley rats were equally randomized into transplantation, model and control group. Except the control group, animal models of liver failure were made by intraperitoneal injection of D-galactosaminein in the transplantation and model groups. One week after modeling, rats in the transplantation group were given 1 mL of adipose-derived mesenchymal stem cells via the tail vein.
RESULTS AND CONCLUSION: Adipose-derived mesenchymal stem cell transplantation successfully upregulated alanine aminotransferase and aspartate aminotransferase levels, and moreover, neatly arranged liver cells, reduced inflammatory cells and intact hepatic lobule were shown on B ultrasound after cell transplantation. All these findings indicate that adipose-derived mesenchymal stem cell transplantation has therapeutic effects on rat liver failure by improving rat’s liver function and pathological changes.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Liver Failure, Liver Function Tests

CLC Number:

R394.2

Hu Xiao-yang, Leng Hui-guo, Mao Cui-yan, Zhang Yuan. Adipose-derived mesenchymal stem cell transplantation for treatment of liver failure[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(32): 4811-4817.

Figures/Tables 2

2.1 脂肪间充质干细胞的培养原代培养4 h后出现贴壁现象(图1A)，24 h换液去除没有贴壁细胞，贴壁细胞主要为三角形或者梭形，折光性比较好，培养至第4天时，细胞明显增多，部分细胞呈现集落样生长，培养至第10天时可达90%融合。传代培养后细胞主要为梭形，传代培养1.5 h出现贴壁现象，12 h出现完全贴壁，传代第3天细胞增殖加快，出现对数生长，传代培养第5天，细胞大完全融合，呈现为线条状细胞群(图1B)。 2.2 脂肪间充质干细胞的鉴定结果免疫组化染色结果显示，第3代脂肪间充质干细胞的CD44阳性表达率为93.5%，CD105阳性表达率91.3%(图2)，且未见CD34、HLA-DR和CD106阳性表达，表明脂肪间充质干细胞表达间充质干细胞表面标志。 2.3 实验动物数量分析动物实验全部进入结果分析，实验动物数量为45只，无脱落。 2.4 肝功能变化移植后，移植组和模型组大鼠天门氨酸转氨酶水平明显上升，且高于对照组(P < 0.05)，同时移植组大鼠天门氨酸转氨酶水平明显低于模型组(P < 0.05；表1)。移植后，移植组和模型组大鼠谷丙转氨酶水平谷丙转氨酶水平明显上升，且明显高于对照组(P < 0.05)，移植组大鼠谷丙转氨酶水平明显低于模型组(P < 0.05；表2)。 2.5 B超检查结果肝脏B超结果显示，对照组大鼠肝实质为细小均匀回声，包膜光滑，血管走行比较清晰，门静脉血管期相性好；模型组大鼠肝实质回声不均匀或呈结节状，比较粗糙，包膜毛糙不平或呈锯齿状，血管狭窄，走行不太清晰，门静脉血流期相性比较地平或消失；移植组大鼠肝实质回声不均匀，包膜欠光滑，血管欠清晰，门静脉血流期相性降低。其中正常对照组无肝功能衰竭阳性大鼠，模型组15只大鼠均肝功能衰竭阳性，移植组有10只大鼠肝功能衰竭阳性。 2.6 肝脏病理组织学形态苏木精-伊红染色结果显示，对照组大鼠肝脏内肝细胞排列比较整齐，没有炎症细胞浸润，肝小叶结构正常；模型组大鼠的肝脏组织淤血肿胀，干细胞出现变形坏死，细胞核碎裂，出现大量炎症细胞，肝小叶结构被破坏，肝窦淤血扩张等肝功能衰竭病理表现；移植组经脂肪间充质干细胞治疗后肝细胞排列尚整齐，炎症细胞减少，肝小叶结构基本比较完整(图3)。"

References

[1] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-946.
[2] Haarer J, Johnson CL, Soeder Y, et al. Caveats of mesenchymal stem cell therapy in solid organ transplantation. Transpl Int. 2015;28(1):1-9.
[3] Ju S, Teng GJ, Lu H, et al. In vivo differentiation of magnetically labeled mesenchymal stem cells into hepatocytes for cell therapy to repair damaged liver. Invest Radiol. 2010;45(10):625-633.
[4] De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012;12(5):574-591.
[5] 戴光荣,刘文娜.乙肝后肝硬化患者胃镜与B超及Child- Pugh分级的相关性研究[J].延安大学学报,2013,11(2): 65.
[6] Gustot T. Beneficial role of G-CSF in acute-on-chronic liver failure: effects on liver regeneration, inflammation/immunoparalysis or both? Liver Int. 2014; 34(4):484-486.
[7] 汤伟亮,赵钢德,董志霞,等.肝衰竭预后危险因素及预后模型建立的研究[J].传染病信息,2011,24(3):159-162.
[8] Struecker B, Raschzok N, Sauer IM. Liver support strategies: cutting-edge technologies. Nat Rev Gastroenterol Hepatol. 2014;11(3):166-176.
[9] 顾广祥,施晓雷,丁义涛.慢加急性肝衰竭病因及其病理生理机制研究进展[J].中华肝胆外科杂志,2011,17(10): 861-864.
[10] Chen M, Hu P, Peng H, et al. Enhanced peripheral γδT cells cytotoxicity potential in patients with HBV-associated acute-on-chronic liver failure might contribute to the disease progression. J Clin Immunol. 2012;32(4):877-885.
[11] 王银银,黄建荣.人工肝治疗肝衰竭研究进展[J].临床内科杂志,2014,31(8):509-512.
[12] Bañares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57(3): 1153-1162.
[13] 何宏亮,李建国,高志良.人工肝和干细胞在肝衰竭治疗中的进展[J].临床肝胆病杂志,2013,29(9):670-673.
[14] Kumar A, Tripathi A, Jain S. Extracorporeal bioartificial liver for treating acute liver diseases. J Extra Corpor Technol. 2011;43(4):195-206.
[15] 游绍莉,刘鸿凌,荣义辉,等.混合型生物人工肝治疗HBV相关慢加急性肝衰竭患者的初步探讨[J].临床肝胆病杂志, 2013,29(9):685-688.
[16] Kordes C, Häussinger D. Hepatic stem cell niches. J Clin Invest. 2013;123(5):1874-1880.
[17] Kingham E, Oreffo RO. Embryonic and induced pluripotent stem cells: understanding, creating, and exploiting the nano-niche for regenerative medicine. ACS Nano. 2013;7(3):1867-1881.
[18] Chen YF, Tseng CY, Wang HW, et al. Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology. 2012;55(4): 1193-1203.
[19] Behbahan IS, Duan Y, Lam A, et al. New approaches in the differentiation of human embryonic stem cells and induced pluripotent stem cells toward hepatocytes. Stem Cell Rev. 2011;7(3):748-759.
[20] Si-Tayeb K, Noto FK, Nagaoka M, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology. 2010;51(1): 297-305.
[21] van Poll D, Parekkadan B, Cho CH, et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology. 2008;47(5):1634- 1643.
[22] Bhave VS, Paranjpe S, Bowen WC, et al. Genes inducing iPS phenotype play a role in hepatocyte survival and proliferation in vitro and liver regeneration in vivo. Hepatology. 2011;54(4):1360-1370.
[23] Xu T, Wang X, Chen G, et al. Autologous bone marrow stem cell transplantation attenuates hepatocyte apoptosis in a rat model of ex vivo liver resection and liver autotransplantation. J Surg Res. 2013;184(2): 1102-1108.
[24] Yovchev MI, Xue Y, Shafritz DA, et al. Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/progenitor cells and mature hepatocytes. Hepatology. 2014;59(1):284-295.
[25] Li T, Yan Y, Wang B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22(6): 845-854.
[26] Zheng L, Chu J, Shi Y, et al. Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17. Cell Biosci. 2013; 3(1):46.
[27] Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell. 2012;10(5):544-555.
[28] Zhu X, He B, Zhou X, et al. Effects of transplanted bone-marrow-derived mesenchymal stem cells in animal models of acute hepatitis. Cell Tissue Res. 2013;351(3):477-486.
[29] Higashimoto M, Sakai Y, Takamura M, et al. Adipose tissue derived stromal stem cell therapy in murine ConA-derived hepatitis is dependent on myeloid-lineage and CD4+ T-cell suppression. Eur J Immunol. 2013;43(11):2956-2968.
[30] Zhang Y, Cai W, Huang Q, et al. Mesenchymal stem cells alleviate bacteria-induced liver injury in mice by inducing regulatory dendritic cells. Hepatology. 2014; 59(2):671-682.
[31] Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology. 2014;59(5):2034-2042.
[32] Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402.
[33] Fiore EJ, Bayo JM, Garcia MG, et al. Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice. Stem Cells Dev. 2015;24(6):791-801.
[34] Hu J, Yang Z, Wang J, et al. Infusion of Trx-1-overexpressing hucMSC prolongs the survival of acutely irradiated NOD/SCID mice by decreasing excessive inflammatory injury. PLoS One. 2013;8(11): e78227.
[35] Seo KW, Sohn SY, Bhang DH, et al. Therapeutic effects of hepatocyte growth factor-overexpressing human umbilical cord blood-derived mesenchymal stem cells on liver fibrosis in rats. Cell Biol Int. 2014; 38(1):106-116.
[36] Du Z, Wei C, Yan J, et al. Mesenchymal stem cells overexpressing C-X-C chemokine receptor type 4 improve early liver regeneration of small-for-size liver grafts. Liver Transpl. 2013;19(2):215-225.
[37] Monsel A, Zhu YG, Gennai S, et al. Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells. Anesthesiology. 2014;121(5):1099-1121.
[38] Volarevic V, Nurkovic J, Arsenijevic N, et al. Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis. Stem Cells. 2014;32(11):2818-2823.
[39] Esrefoglu M. Role of stem cells in repair of liver injury: experimental and clinical benefit of transferred stem cells on liver failure. World J Gastroenterol. 2013; 19(40):6757-6773.
[40] 刘波,董静,张骏飞,等.人脐带间充质干细胞治疗慢加急性肝衰竭患者近期疗效与安全性分析[J].实用肝脏病杂志, 2013,16(1):29-31.
[41] Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1(10):725-731.
[42] Zhu W, Shi XL, Xiao JQ, et al. Effects of xenogeneic adipose-derived stem cell transplantation on acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int. 2013;12(1):60-67.
[43] Zhang Y, Chen XM, Sun DL. Effects of coencapsulation of hepatocytes with adipose-derived stem cells in the treatment of rats with acute-on-chronic liver failure. Int J Artif Organs. 2014; 37(2):133-141.
[44] Zhang S, Liu P, Chen L, et al. The effects of spheroid formation of adipose-derived stem cells in a microgravity bioreactor on stemness properties and therapeutic potential. Biomaterials. 2015;41:15-25.
[45] Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1(10):725-731.
[46] Wan Z, You S, Rong Y, et al. CD34+ hematopoietic stem cells mobilization, paralleled with multiple cytokines elevated in patients with HBV-related acute-on-chronic liver failure. Dig Dis Sci. 2013;58(2): 448-457.